 CAMBRIDGE, Mass., May 17, 2022 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following upcoming investor conferences: 